Fatigue in Primary Biliary Cholangitis: No Place for Rituximab

Potential conflict of interest: Nothing to report. See Article on Page 1646 Patients with primary biliary cholangitis (PBC) have experienced major therapeutic progress during the last four decades. An effective first‐line therapy, ursodeoxycholic acid (UDCA), is available from which all patients, responders as well as “incomplete” responders, appear to benefit according to the newest data.1 Increasing insight into the mechanisms and sites of...